Valuation: Armata Pharmaceuticals, Inc.

Market Cap 185M 161M 150M 138M 260M 17.67B 265M 1.77B 695M 8.81B 696M 681M 29.07B P/E 2026 *
-1.33x
P/E 2027 * -3.77x
Enterprise Value 185M 161M 150M 138M 260M 17.67B 265M 1.77B 695M 8.81B 696M 681M 29.07B EV / Sales 2026 *
84.3x
EV / Sales 2027 * 67.4x
Free-Float
31.49%
Yield 2026 *
-
Yield 2027 * -
1 day+11.23%
1 week-1.94%
Current month+11.23%
1 month-14.26%
3 months-43.19%
6 months-34.84%
Current year-19.59%
1 week 4.45
Extreme 4.45
5.14
1 month 3.48
Extreme 3.48
6.22
Current year 3.48
Extreme 3.48
14.98
1 year 2.36
Extreme 2.36
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
09/03/26 Free

Director

25,640 0.0704%
Change 5-day change 1-year change 3-year change Capi.($)
+11.23%-1.94%+98.82%+36.86% 185M
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.47%-5.83%+23.72%+62.42% 51.97B
-0.62%+1.27%-14.06%-13.50% 23.33B
+0.10%-6.00%-9.42%+344.47% 21.34B
+2.18%-0.71%+33.98%-25.15% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+0.27%-1.34%+47.77%+165.22% 13.84B
+2.09%+0.56%+439.92%+166.12% 12.12B
+3.62%-12.56%+59.51%+149.39% 11.14B
Average +2.88%-2.29%+90.73%+127.88% 22.28B
Weighted average by Cap. +1.22%-1.95%+57.99%+109.57%

Financials

2026 *2027 *
Net sales 2.2M 1.91M 1.79M 1.64M 3.09M 210M 3.14M 21.05M 8.24M 105M 8.26M 8.08M 345M 2.75M 2.39M 2.23M 2.05M 3.86M 262M 3.93M 26.31M 10.3M 131M 10.33M 10.1M 431M
Net income -172M -149M -139M -128M -241M -16.38B -246M -1.64B -644M -8.17B -646M -631M -26.95B -66.35M -57.66M -53.84M -49.42M -93.19M -6.32B -94.81M -635M -249M -3.15B -249M -244M -10.4B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
03/08/26 $5.050 +11.23% 60,161
31/07/26 $4.540 -5.02% 30,752
30/07/26 $4.780 +4.60% 64,089
29/07/26 $4.570 -3.38% 97,502
28/07/26 $4.730 -8.16% 59,324
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.050USD
Average target price
17.50USD
Spread / Average Target
+246.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock